Invokana (canagliflozin) Invokana (canagliflozin), an SGLT2 inhibitor, is now a first-line option for Type 2 diabetes patients with cardiovascular disease, high cardiovascular risk, heart failure, or chronic kidney disease (CKD), regardless of baseline A1C, according to the 2022 American Diabetes Association (ADA) Standards of Care in Diabetes
doi:10.3390/nu13030814 Holesh JE, Aslam S, Martin, A
The legal status guide and regulation update tracker provide current information on the legal landscape for each compound
Claus TH, Pan CQ, Buxton JM, et al
According to the Alliance for Pharmacy Compounding (APC), the proposed regulations exceed federal standards in 57 instances
This study has been replicated in variations (different tendons, different injury models) primarily within the Zagreb lab